# Patient Satisfaction with Aesthetic Outcomes Following OnabotulinumtoxinA Treatment for Chronic Migraine: A Cross-Sectional Study

**Authors:** Magdalena Boczarska-Jedynak, Marta Bott-Karoń, Karol Marschollek, Mariola Antolak, Maciej Świat, Marta Waliszewska-Prosół

PMC · DOI: 10.3390/toxins17060292 · 2025-06-08

## TL;DR

This study found that patients with chronic migraine who received OnabotulinumtoxinA injections reported improved facial aesthetics and high satisfaction with treatment outcomes.

## Contribution

The study is the first to comprehensively assess patient satisfaction with aesthetic outcomes following OnabotulinumtoxinA treatment for chronic migraine.

## Key findings

- OnabotulinumtoxinA significantly reduced wrinkle severity (p < 0.0001).
- 74.2% of patients reported aesthetic improvement post-treatment.
- 76.7% of patients stated the treatment met or exceeded their expectations.

## Abstract

OnabotulinumtoxinA (OnaBoNT-A) is approved for chronic migraine prevention and follows the PREEMPT protocol with injections in the glabellar and forehead regions. While aesthetic changes are considered a side effect, their effect on patient satisfaction has not been thoroughly assessed. This study evaluated patient satisfaction with facial aesthetic outcomes after repeated OnaBoNT-A treatment for chronic migraine. Conducted at specialist headache centers, it included adult patients with chronic migraine who had received at least three OnaBoNT-A cycles. Participants completed a structured questionnaire on demographics, migraine history, facial wrinkles and age perception, appearance satisfaction, psychological impact, treatment satisfaction, and adverse aesthetic events. A total of 124 patients (92.7% female; median age 42.5 years) participated. OnaBoNT-A reduced wrinkle severity (p < 0.0001). Most patients (74.2%) reported aesthetic improvement post-treatment. The majority of patients (76.7%) declared that treatment met or exceeded expectations. 32% reported looking younger post-treatment, with a median perceived age difference of 5 years. Adverse event frequency was similar to pivotal trial outcomes, mostly mild, with no treatment discontinuations. OnaBoNT-A for chronic migraine, following the PREEMPT protocol, provides significant therapeutic benefits and high patient satisfaction regarding aesthetic outcomes. Although aesthetic side effects were generally mild, they were not uncommon.

## Full-text entities

- **Diseases:** headache (MESH:D006261), Chronic Migraine (MESH:D008881)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12197606/full.md

---
Source: https://tomesphere.com/paper/PMC12197606